von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. [electronic resource]
Producer: 20080918Description: 860-5; discussion 865-6 p. digitalISSN:- 1527-3792
- Aged
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- therapeutic use
- Axitinib
- Benzenesulfonates -- therapeutic use
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Chi-Square Distribution
- DNA Primers
- Female
- Humans
- Imidazoles -- therapeutic use
- Indazoles -- therapeutic use
- Indoles -- therapeutic use
- Kidney Neoplasms -- drug therapy
- Logistic Models
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Metastasis
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Prognosis
- Pyridines -- therapeutic use
- Pyrroles -- therapeutic use
- Sorafenib
- Sunitinib
- Survival Rate
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- von Hippel-Lindau Disease -- genetics
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.